Dr. Javier Menendez has done work on Orlistat and her2+ breast cancer cell lines
As I recall it was synergistic with Herceptin. unfortunately if I remember correctly, the concentrations required could not be met with oral orlistat, as it is not absorbed (hence its effect by carrying away fat with it down the GI tract without their being absorbed also). To work it would have to be provided parenterally (IV or IM) and its effects given in such a manner have not yet been worked out from what I understand
Roche markets both drugs--so it would be a natural for them to try to market the combo against her2neu + breast cancer.
Looks like a lot of work would be needed to determine the correct dose, administration, safety, etc as the work was done on cell lines (in vitro)
|